

## PainChek reports material sales momentum in UK

**Sydney, Australia, 26 March 2026** – PainChek Ltd (ASX: PCK), developer of the world’s first AI-powered pain assessment and monitoring application, is pleased to announce it has already achieved strong quarterly growth in the UK aged care market, with 4,000 new contracted licenses providing 9% quarter on quarter growth and an additional \$230,000 AUD ARR once implemented. Total UK global licenses and ARR will be reported in the upcoming quarterly business update post March 31<sup>st</sup> 2026.

This growth reflects sustained demand for PainChek’s clinically validated technology and builds on the positive outcomes data being observed across the UK. Facilities utilising PainChek are increasingly reporting improved pain identification and management, supporting enhanced resident care and operational efficiencies.

Importantly, PainChek is being recognised as a priority solution within aged care settings, with providers placing greater emphasis on effective pain management relative to other technology categories such as falls detection. This prioritisation highlights the critical role pain assessment plays in improving quality of care and meeting regulatory expectations.

PainChek’s continued expansion in the UK is supported by a growing body of evidence demonstrating its impact across large-scale deployments, further reinforcing its position as a leading solution in the sector.

Beyond the UK, the Company is also making positive progress in North America, where early commercial and strategic initiatives continue to advance. In addition, development and early deployment of PainChek’s Infants product is progressing well, and the Company looks forward to providing updates on these initiatives in due course.

PainChek CEO Philip Daffas said: “We remain well positioned to capitalise on increasing global demand for digital health solutions in aged care settings, with major market opportunities in North America and other verticals still ahead of us.”

This announcement has been approved for release by the Board.

For more information:

Natalie Climo  
Company Secretary, PainChek  
[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)  
02 8016 2875

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

## About PainChek

[PainChek](#)® is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom.

PainChek® has contracts with over 2,000 aged care facilities, with more than 18,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>